AbbVie Inc (ABBV)vsApollomics Inc. Class A Ordinary Shares (APLM)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
APLM
Apollomics Inc. Class A Ordinary Shares
$13.08
+1.75%
HEALTHCARE · Cap: $28.71M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 679909% more annual revenue ($61.16B vs $8.99M). ABBV leads profitability with a 6.9% profit margin vs -121.6%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
APLM
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Intrinsic value data unavailable for APLM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Strong operational efficiency at 329.8%
Revenue surging 380.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1305.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : APLM
The strongest argument for APLM centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 380.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : APLM
The primary concerns for APLM are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while APLM is a hypergrowth play — different risk/reward profiles.
APLM carries more volatility with a beta of 1.83 — expect wider price swings.
APLM is growing revenue faster at 380.8% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Apollomics Inc. Class A Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company is headquartered in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?